ClinicalTrials.gg
CompletedNCT06699355Updated Nov 21, 2024

A Study to Evaluate the Drug-Drug Interaction Between Enlicitide Decanoate (MK-0616) and Atorvastatin in Healthy Adult Participants (MK-0616-024)

A Phase 1 interventional study of Enlicitide Decanoate and Atorvastatin in Healthy, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-11-21.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2023, 2 years 10 months ago, and no results have been posted to the registry.
  • Registered 1 year after the study started (first participant enrolled Nov 2023, registered Nov 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Study summary

The goal of this study is to learn what happens to enlicitide decanoate and atorvastatin in a healthy person's body over time. Researchers want to learn what happens to enlicitide decanoate in the body when it is given with and without another medicine called atorvastatin and what happens to atorvastatin in the body when it is given with or without enlicitide decanoate.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to the first dosing based on participant self-reporting
  • Medically healthy with no medical history, physical examination, laboratory profiles, standard and orthostatic vital signs, and (ECGs)

Exclusion criteria

Exclusion Criteria:

  • History of gastrointestinal disease which may affect food and drug absorption or has had a gastric bypass or similar surgery
  • History of cancer ()
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Atorvastatin

    Participants receive a single oral dose of atorvastatin (Treatment A) on Day 1.

    Drug: Atorvastatin

  • Experimental
    Enlicitide Decanoate + Atorvastatin

    Participants receive a single oral dose of enlicitide decanoate plus a single oral dose of atorvastatin (Treatment B) on Day 1.

    Drug: Enlicitide Decanoate · Drug: Atorvastatin

  • Experimental
    Enlicitide Decanoate

    Participants receive a single oral dose of enlicitide decanoate (Treatment C) on Day 1.

    Drug: Enlicitide Decanoate

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Atorvastatin and its Metabolites

    Blood samples will be collected to determine the AUC0-Inf of atorvastatin and its metabolites.

    Time frame: At designated timepoints (up to approximately 8 days)

  2. Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Atorvastatin and its Metabolites

    Blood samples will be collected to determine the AUC0-Last of atorvastatin and its metabolites.

    Time frame: At designated timepoints (up to approximately 8 days)

  3. Maximum Plasma Concentration (Cmax) of Atorvastatin and its Metabolites

    Blood samples will be collected to determine the Cmax of atorvastatin and its metabolites.

    Time frame: At designated timepoints (up to approximately 8 days)

  4. Time to Maximum Plasma Concentration (Tmax) of Atorvastatin and its Metabolites

    Blood samples will be collected to determine the Tmax of atorvastatin and its metabolites.

    Time frame: At designated timepoints (up to approximately 8 days)

  5. Apparent Terminal Half-Life (t1/2) of Atorvastatin and its Metabolites

    Blood samples will be collected to determine the t1/2 of atorvastatin and its metabolites.

    Time frame: At designated timepoints (up to approximately 8 days)

  6. Apparent Clearance (CL/F) of Atorvastatin

    Blood samples will be collected to determine the CL/F of atorvastatin.

    Time frame: At designated timepoints (up to approximately 8 days)

  7. Apparent Volume of Distribution (Vz/F) of Atorvastatin

    Blood samples will be collected to determine the Vz/F of atorvastatin.

    Time frame: At designated timepoints (up to approximately 8 days)

  8. Area Under the Concentration-Time Curve from Time 0 to 24 Hours (AUC0-24hrs) of Enlicitide Decanoate

    Blood samples will be collected to determine the AUC0-24hrs of enlicitide decanoate.

    Time frame: At designated timepoints (up to approximately 24 hours)

  9. Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of Enlicitide Decanoate

    Blood samples will be collected to determine the AUC0-Inf of enlicitide decanoate.

    Time frame: At designated timepoints (up to approximately 8 days)

  10. Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of Enlicitide Decanoate

    Blood samples will be collected to determine the AUC0-Last of enlicitide decanoate.

    Time frame: At designated timepoints (up to approximately 8 days)

  11. Maximum Plasma Concentration (Cmax) of Enlicitide Decanoate

    Blood samples will be collected to determine the Cmax of enlicitide decanoate.

    Time frame: At designated timepoints (up to approximately 8 days)

  12. Time to Maximum Plasma Concentration (Tmax) of Enlicitide Decanoate

    Blood samples will be collected to determine the Tmax of enlicitide decanoate.

    Time frame: At designated timepoints (up to approximately 8 days)

  13. Apparent Terminal Half-Life (t1/2) of Enlicitide Decanoate

    Blood samples will be collected to determine the t1/2 of enlicitide decanoate.

    Time frame: At designated timepoints (up to approximately 8 days)

  14. Apparent Clearance (CL/F) of Enlicitide Decanoate

    Blood samples will be collected to determine the CL/F of enlicitide decanoate.

    Time frame: At designated timepoints (up to approximately 8 days)

  15. Apparent Volume of Distribution (Vz/F) of Enlicitide Decanoate

    Blood samples will be collected to determine the Vz/F of enlicitide decanoate.

    Time frame: At designated timepoints (up to approximately 8 days)

Secondary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 10 weeks

  2. Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 6 weeks

07

Study locations

1 site
  • Celerion (Site 0001)
    Lincoln, Nebraska 68502, United States
08

References and documents

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2023 to primary completion in Dec 2023, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2024
First posted
Nov 21, 2024
StartActual
Nov 8, 2023
Primary completionActual
Dec 29, 2023
CompletionActual
Dec 29, 2023
Last update
Nov 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06699355
Responsible party
Sponsor
First posted
Nov 21, 2024
Start date
Nov 8, 2023
Primary completion
Dec 29, 2023
Completion
Dec 29, 2023
Last update
Nov 21, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: MK-0616 · Atorvastatin

Start the discussion